Key Takeaway: Telix will participate in the 2025 Society of Urologic Oncology Annual Meeting, which focuses on advancements in urologic cancer care. The company plans to showcase its Phase 3 precision imaging and therapeutic trials specifically targeting prostate and kidney cancer. This event is recognized as a significant platform for discussing innovations in cancer treatment.
Price reaction · baseline $9.95 (2025-11-28 close) · hit pre-market · 2 other TLX headline(s) in the window, move may be shared
day 0 close · peak
-1.3%
Market Sentiment Analysis
POSITIVE FACTORS
Telix is participating in a leading international congress.
Showcasing advancements in urologic cancer care.
Highlighting Phase 3 trials for prostate and kidney cancer.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease
Full Press Release Details
Join Telix at the 2025 Society of Urologic Oncology (SUO) Annual Meeting, one of the world’s leading international congresses dedicated to advances in urologic cancer care. Telix will be showcasing its Phase 3 precision imaging and therapeutic trials in prostate and kidney cancer.
Frequently Asked Questions
What is the SUO 2025 Annual Meeting?
The SUO 2025 Annual Meeting is a leading congress focused on urologic cancer care.
What will Telix showcase at SUO 2025?
Telix will showcase its Phase 3 precision imaging and therapeutic trials.
Which cancers are targeted in Telix's trials?
Telix's trials focus on prostate and kidney cancer.